oxybutynin hydrochloride

Urinary frequency, urgency and incontinenceNeurogenic bladder instability and nocturnal enuresis

2.5–5 mg 2 to 3 times a day; maximum 5 mg 4 times a dayXL: 5–20 mg once daily Patches: 1 patch (36 mg) twice weekly

Molecular weight :393.9

%Protein binding :83–85

%Excreted unchanged in urine : <0.1

Volume of distribution (L/kg) :193 litres

half-life – normal/ESRD (hrs) :1.1–3 (XL: 12–13) /–

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Dialysed. Dose as in normal renal function

HD :Dialysed. Dose as in normal renal function

HDF/high flux :Dialysed. Dose as in normal renal function

CAV/VVHD :Dialysed. Dose as in normal renal function

Potentially hazardous interactions with other drugsOther antimuscarinic agents: increased antimuscarinic effects

–

Oral, topical

–

–

Start with a low dose in elderly patients and those with renal impairment, and increase according to response